• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

脓毒症患者中性粒细胞和单核细胞中纤溶酶原激活物抑制剂

Inhibitors of plasminogen activator in neutrophils and mononuclear cells from septic patients.

作者信息

Haj M A, Robbie L A, Adey G D, Bennett B

机构信息

Department of Medicine and Therapeutics, University of Aberdeen Medical School, Foresterhill, UK.

出版信息

Thromb Haemost. 1995 Dec;74(6):1528-32.

PMID:8772232
Abstract

Leucocytes, both polymorphs and mononuclear cells, play a variety of roles in the evolution of human response to sepsis, both local and generalised. In this study, inhibitors of plasminogen activator were measured in leucocytes from normal and septic patients. Plasminogen activator inhibitor-1 (PAI-1) was identified in polymorphs from normal individuals and levels rose significantly in polymorphs from septic patients: neutrophils from normal subjects did not contain PAI-2 but this protein was detectable in significant quantities in polymorph preparations from septic patients. In contrast, mononuclear cells from normal and septic patients contained no detectable quantities of PAI-1. Significant amounts of PAI-2 were present in normal mononuclear cells, and the levels rose significantly in monocytes from septic patients. PAI-2 is thus here identified in human subjects, distinct from those with pregnancy or malignancy, as playing a role in a pathological process. The increased levels of both inhibitors produced by leucocytes may clearly contribute directly to the persistence of fibrin, a characteristic feature of the response to infection, local or general; they may thus participate in successful localisation of infections (abscess formation etc.) and in the evolution of the major systemic complications of disseminated sepsis characterised by microvascular occlusion by fibrin such as renal failure, shock lung or digital ischaemia.

摘要

白细胞,包括多形核白细胞和单核细胞,在人类对脓毒症的局部和全身反应的演变中发挥着多种作用。在本研究中,检测了正常患者和脓毒症患者白细胞中纤溶酶原激活物抑制剂。在正常个体的多形核白细胞中鉴定出纤溶酶原激活物抑制剂-1(PAI-1),脓毒症患者多形核白细胞中的PAI-1水平显著升高:正常受试者的中性粒细胞不含PAI-2,但在脓毒症患者的多形核细胞制剂中可检测到大量该蛋白。相比之下,正常患者和脓毒症患者的单核细胞中未检测到PAI-1。正常单核细胞中存在大量PAI-2,脓毒症患者单核细胞中的PAI-2水平显著升高。因此,在非妊娠或非恶性肿瘤的人类受试者中,PAI-2在病理过程中发挥作用。白细胞产生的两种抑制剂水平升高可能直接导致纤维蛋白持续存在,这是局部或全身感染反应的一个特征;它们可能因此参与感染的成功定位(脓肿形成等)以及以纤维蛋白微血管阻塞为特征的播散性脓毒症主要全身并发症的演变,如肾衰竭、休克肺或手指缺血。

相似文献

1
Inhibitors of plasminogen activator in neutrophils and mononuclear cells from septic patients.脓毒症患者中性粒细胞和单核细胞中纤溶酶原激活物抑制剂
Thromb Haemost. 1995 Dec;74(6):1528-32.
2
Increase of plasminogen activator inhibitor levels predicts outcome of leukocytopenic patients with sepsis.纤溶酶原激活物抑制剂水平升高可预测脓毒症白细胞减少患者的预后。
Thromb Haemost. 1996 Jun;75(6):902-7.
3
Activation of the fibrinolytic system and utilization of the coagulation inhibitors in sepsis: comparison with severe sepsis and septic shock.脓毒症中纤溶系统的激活及凝血抑制剂的利用:与严重脓毒症和脓毒性休克的比较
Intensive Care Med. 2001 Dec;27(12):1853-9. doi: 10.1007/s00134-001-1139-8. Epub 2001 Nov 10.
4
TAFI and PAI-1 levels in human sepsis.人类脓毒症中的凝血酶激活的纤溶抑制物(TAFI)和纤溶酶原激活物抑制剂-1(PAI-1)水平
Thromb Res. 2006;118(2):205-12. doi: 10.1016/j.thromres.2005.06.007. Epub 2005 Jul 11.
5
Plasminogen activator inhibitor 2 and urokinase-type plasminogen activator in plasma and leucocytes in patients with severe sepsis.
Br J Haematol. 2000 May;109(2):342-8. doi: 10.1046/j.1365-2141.2000.02057.x.
6
Plasminogen activators (t-PA and u-PA) and plasminogen activators inhibitors (PAI-1 and PAI-2) in some myeloproliferative syndromes.某些骨髓增殖性综合征中的纤溶酶原激活剂(组织型纤溶酶原激活剂和尿激酶型纤溶酶原激活剂)及纤溶酶原激活剂抑制剂(PAI - 1和PAI - 2)
Med Sci Monit. 2000 Jul-Aug;6(4):684-91.
7
Concentrations of plasminogen activators and their inhibitors in blood preconceptionally, during and after pregnancy.孕前、孕期及产后血液中纤溶酶原激活剂及其抑制剂的浓度。
Eur J Obstet Gynecol Reprod Biol. 2006 Sep-Oct;128(1-2):22-8. doi: 10.1016/j.ejogrb.2006.02.004. Epub 2006 Apr 11.
8
Early inhibition of activated fibrinolysis predicts microbial infection, shock and mortality in febrile medical patients.早期抑制激活的纤溶系统可预测发热内科患者的微生物感染、休克及死亡率。
Thromb Haemost. 2001 Aug;86(2):543-9.
9
Effect of Tisseel on expression of tissue plasminogen activator and plasminogen activator inhibitor-1.纤维蛋白黏合剂对组织型纤溶酶原激活物及纤溶酶原激活物抑制剂-1表达的影响
Fertil Steril. 2004 Jun;81(6):1657-64. doi: 10.1016/j.fertnstert.2003.12.022.
10
The tissue factor and plasminogen activator inhibitor type-1 response in pediatric sepsis-induced multiple organ failure.小儿脓毒症诱导的多器官功能衰竭中组织因子和纤溶酶原激活物抑制剂-1的反应
Thromb Haemost. 2002 Feb;87(2):218-23.

引用本文的文献

1
All tangled up: interactions of the fibrinolytic and innate immune systems.错综复杂:纤维蛋白溶解系统与先天免疫系统的相互作用。
Front Med (Lausanne). 2023 Jun 2;10:1212201. doi: 10.3389/fmed.2023.1212201. eCollection 2023.
2
The role of plasminogen activator inhibitor-2 in pneumococcal meningitis.纤溶酶原激活物抑制剂-2在肺炎球菌性脑膜炎中的作用
Acta Neuropathol Commun. 2022 Oct 29;10(1):155. doi: 10.1186/s40478-022-01461-1.
3
Induction of the plasminogen activator system accompanies peripheral nerve regeneration after sciatic nerve crush.
坐骨神经挤压伤后,纤溶酶原激活物系统的诱导伴随着周围神经再生。
J Neurosci. 2001 Jun 15;21(12):4336-47. doi: 10.1523/JNEUROSCI.21-12-04336.2001.
4
Fibrinolytic changes in a patient with toxic shock syndrome; release of active u-PA.中毒性休克综合征患者的纤溶变化;活性尿激酶型纤溶酶原激活物的释放
Intensive Care Med. 1998 Mar;24(3):258-61. doi: 10.1007/s001340050561.